The Effectiveness Of Salvage Chemotherapy With S-1 For Pretreated Nsclc Patients: Single Center Retrospective Study

A number of clinical trials with the combination of S-1 and platinum have shown a clinical effectiveness in first-line chemotherapy of non-small cell lung cancer (NSCLC). But there is no definite role of S-1 containing chemotherapy in the salvage setting. The aim of this study is to assess the effectiveness of S-1 as salvage chemotherapy in patients with NSCLC who failed prior chemotherapy. The medical charts of all patients undergoing chemotherapy in internal medicine and thoracic surgery between March 2010 and Jan 2014 were reviewed. 20 patients received S-1 alone or S-1 containing chemotherapy as salvage treatment, where male are 17 and female are 3 (M: F 17:3). Of them, 12 patients received S-1 as second-line (60%) and 8 patients received S-1 as beyond second-line (40%). The median age at diagnosis was 65 years .The most common prior chemotherapy were CBDCA plus pemetrexed and CBDCA plus paclitaxel. Among the patients who could be evaluated, partial response was observed in 2 patients. Overall response rate (ORR) and disease control rate (DCR) were 11% (2/18) and 72% (13/18) in the patients with measurable lesions. Median overall survival (OS) from initial treatment and S-1 treatment were 462 (95%CI: 57-866) and 222 (95%CI: 147-227) days. Median time to treatment failure (TTF) from S-1 treatment was 98 (95%CI: 57-139) days. Regarding the effectiveness according to histology type, significant differences of effectiveness were observed between adenocarcinoma and squamous cell carcinoma (Median PFS: 84 (95% CI: 63-132) vs. 175 (95% CI: 75-275 days, Log-rank p = 0.057) days. Although this study is small, retrospective and limited by not being controlled, it is suggested that S-1 have a potential role as salvage therapy in NSCLC, especially in squamous histology. Updated data will be presented at the meeting.